High-molecular-weight hyaluronan – a possible new treatment for sepsis-induced lung injury: a preclinical study in mechanically ventilated rats

Citation
Liu, Yung-Yang, Cheng-Hung Lee, Rejmon Dedaj, Hang Zhao, Hicham Mrabat, Aviva Sheidlin, Olga Syrkina, Pei-Ming Huang, Hari G Garg, Charles A Hales, and Deborah A Quinn. 2008. High-molecular-weight hyaluronan – a possible new treatment for sepsis-induced lung injury: a preclinical study in mechanically ventilated rats. Critical Care 12(4): R102.

Published Version
doi:10.1186/cc6982

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:4882986

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Research

High-molecular-weight hyaluronan – a possible new treatment for sepsis-induced lung injury: a preclinical study in mechanically ventilated rats

Yung-Yang Liu1,2,3,4, Cheng-Hung Lee1,2,5, Rejmon Dedaj1,2, Hang Zhao1,2, Hicham Mrabat1,2, Aviva Sheidlin6, Olga Syrkina1,2,7, Pei-Ming Huang1,2,8, Hari G Garg1,2, Charles A Hales1,2 and Deborah A Quinn1,2

1Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street Boston, MA 02114, USA
2Harvard Medical School, 25 Shattuck St, Boston, MA, 02115 USA
3Chest Department, Taipei Veterans General Hospital, Sec 2, Shih-Pai Rd, Taipei, 11217, Taipei, Taiwan
4National Yang-Ming University, School of Medicine, No.155, Sec.2, Linong Street, Taipei, 112 Taiwan
5Department of Internal Medicine, National Cheng Kung University Hospital, 138 Sheng-Li Road, Tainan, 70428 Taiwan
6Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142 USA
7Shriners Burn Hospital, 51 Blossom Street, Boston, MA 02114 USA
8Department of Traumatology and Surgery, National Taiwan University Hospital, No. 7, Chung-Shan S. Road, Taipei 100, Taiwan

Corresponding author: Deborah A Quinn, dquinn1@partners.org

Received: 29 Mar 2008 Revisions requested: 8 May 2008 Revisions received: 14 Jun 2008 Accepted: 8 Aug 2008 Published: 8 Aug 2008

Critical Care 2008, 12:R102 (doi:10.1186/cc6982)

Abstract

Introduction Mechanical ventilation with even moderate-sized tidal volumes synergistically increases lung injury in sepsis and has been associated with proinflammatory low-molecular-weight hyaluronan production. High-molecular-weight hyaluronan (HMW HA), in contrast, has been found to be anti-inflammatory. We hypothesized that HMW HA would inhibit lung injury associated with sepsis and mechanical ventilation.

Methods Sprague–Dawley rats were randomly divided into four groups: nonventilated control rats; mechanical ventilation plus lipopolysaccharide (LPS) infusion as a model of sepsis; and mechanical ventilation plus lipopolysaccharide (LPS) plus HMW HA (1,600 kDa) pretreatment; and mechanical ventilation plus lipopolysaccharide (LPS) plus low-molecular-weight hyaluronan (35 kDa) pretreatment. Rats were mechanically ventilated with low (7 ml/kg) tidal volumes. LPS (1 or 3 mg/kg) or normal saline was infused 1 hour prior to mechanical ventilation. Animals received HMW HA or low-molecular-weight hyaluronan via the intraperitoneal route 18 hours prior to the study or received HMW HA (0.025%, 0.05% or 0.1%) intravenously 1 hour after injection of LPS. After 4 hours of ventilation, animals were sacrificed and the lung neutrophil and monocyte infiltration, the cytokine production, and the lung pathology score were measured.

Results LPS induced lung neutrophil infiltration, macrophage inflammatory protein-2 and TNFα mRNA and protein, which were decreased in the presence of both 1,600 kDa and 35 kDa hyaluronan pretreatment. Only 1,600 kDa hyaluronan completely blocked both monocyte and neutrophil infiltration and decreased the lung injury. When infused intravenously 1 hour after LPS, 1,600 kDa hyaluronan inhibited lung neutrophil infiltration, macrophage inflammatory protein-2 mRNA expression and lung injury in a dose-dependent manner. The beneficial effects of hyaluronan were partially dependent on the positive charge of the compound.

Conclusions HMW HA may prove to be an effective treatment strategy for sepsis-induced lung injury with mechanical ventilation.

BAL: bronchoalveolar lavage; CMC: sodium carboxymethyl cellulose; ELISA: enzyme-linked immunosorbent assay; HA: hyaluronan; HAS: hyaluronan synthase; HMW HA: high-molecular-weight hyaluronan; IFN: interferon; IL: interleukin; JNK: c-Jun NH2-terminal kinase; LMW HA: low-molecular-weight hyaluronan; LPS: lipopolysaccharide; MIP-2: macrophage inflammatory protein-2; PCR: polymerase chain reaction; RT: reverse transcriptase; TNF: tumor necrosis factor.
Introduction

Hyaluronan (HA), an important component of the extracellular matrix, is composed of repeating disaccharide units containing alternating β-glucuronic acid and N-acetyl glucosamine. HA has been shown to produce distinct biological effects depending on the molecular weight. HA is synthesized by hyaluronan synthase (HAS) that is located in the cell membrane, and is secreted into the interstitial space [1]. In mammalian cell culture, HAS 1 and HAS 2 produce high-molecular-weight hyaluronan (HMW HA), whereas HAS 3 produces low-molecular-weight hyaluronan (LMW HA) [2,3].

HA has been identified as an important modulator in many physiological and pathological processes. Under physiological conditions, HA exists predominantly in the HMW HA form (>500 kDa), and maintains the structural integrity of the extracellular matrix in the lungs. In disease conditions during inflammation, LMW HA (<500 kDa) is produced either by depolymerization of HMW HA via oxygen radicals and enzymatic degradation by hyaluronidase, β-glucuronidase, and hexosaminidase or by de novo synthesis through HAS 3 [4].

LMW HA can function as an intracellular signaling molecule in inflammation and has been found to be proinflammatory [5,6]. We have found that LMW HA from stretched lung enhances IL-8 expression, and that LMW HA production by HAS 3 mediated ventilator-induced lung injury [7,8]. On the contrary, HMW HA can block inflammation. Transgenic HAS 2 mice that overexpress HMW HA have been found to be protected from bleomycin-induced lung injury [9]. We hypothesized that systemic administration of HMW HA would decrease sepsis-induced lung injury with mechanical ventilation by inhibiting cytokine production and lung inflammation.

Materials and methods

Animals

The present study was approved by the Massachusetts General Hospital Subcommittee on Research Animal Care. Sprague–Dawley viral-free rats, all in the growing phase, weighing between 185 and 225 g, were obtained from Charles River Laboratories (Wilmington, MA, USA).

Ventilator protocol

The animals were anesthetized by intraperitoneal ketamine (90 mg/kg) (Abbott Laboratories, Chicago, IL, USA) and xylazine (10 mg/kg; Burns Veterinary Supply Inc., Rockville Centre, NY, USA) while breathing room air. Throughout the experiment, the animals were placed in a supine position on a heating blanket and the body temperature was monitored with a rectal probe. PE 240 tubing (outer diameter, 2.42 mm; inner diameter, 1.67 mm; Becton Dickson Infusion Therapy System Inc., Sandy, UT, USA) was inserted into the trachea and connected to a Harvard apparatus ventilator (model 55-7058; Harvard Apparatus, Holliston, MA, USA). The rats were then ventilated with a tidal volume of 7 ml/kg with a rate of 85 to 100 breaths per minute.

The end-tidal carbon dioxide pressure was monitored intermittently by a microcapnograph (Columbus Instruments, Columbus, OH, USA), and was maintained between 35 and 45 mmHg by adjusting the ventilator respiratory rate. The volume was increased by 5 ml/min to correct the air loss from the sample flow adaptor during monitoring of the end-tidal carbon dioxide. The peak inspiratory airway pressure was measured every 30 minutes with a pressure transducer amplifier (Gould Instrument System, Valley View, OH, USA) connected to the tubing at the proximal end of the tracheostomy.

The mean arterial pressure was measured every 30 minutes during mechanical ventilation using the same pressure transducer amplifier connected to PE 10 tubing (outer diameter, 0.61 mm; inner diameter, 0.28 mm; Becton Dickson Infusion Therapy System Inc., Sandy, Ut, USA) ending in the common carotid artery. During the period of ventilator use, intraperitoneal ketamine 0.05 mg/g and xylazine 0.005 mg/g were administered every 30 minutes, and 0.9% NaCl was infused, as needed, to maintain systolic blood pressure >90 mmHg. Harvesting of lung and bronchoalveolar lavage (BAL) was performed after 4 hours of mechanical ventilation.

Model of lipopolysaccharide-induced lung injury with mechanical ventilation and pretreatment with hyaluronan

Sprague–Dawley rats were randomly divided into four groups: nonventilated control rats; mechanically ventilated rats with lipopolysaccharide (LPS) infusion as a model of sepsis; mechanical ventilation plus LPS infusion with HMW HA (1,600 kDa) pretreatment; and mechanical ventilation plus LPS infusion with LMW HA (35 kDa) pretreatment. Rats were mechanically ventilated with a low tidal volume (7 ml/kg) (n = 5 or 6 rats/group) for 4 hours. Rats received 3 ml of 0.35% of 1,600 kDa or 35 kDa (Genzyme Corp., Cambridge, MA, USA) pretreatment via the intraperitoneal route 18 hours prior to the beginning of study.

All HA preparations were sterile and were protein free and LPS free, to avoid known confounding effects of HA [10]. The size and amount of HA was chosen based on previous work that found HMW HA (>780 kDa) given intraperitoneally 18 hours before injection of concavalin protected against concavalin-induced liver toxicity. A dose response was found in this model, and 0.35% HMW HA was most effective [11]. We have shown that 1,600 kDa HA is the predominant size in normal rat lung [7]. Based on these findings, we used 0.35% of 1,600 kDa given intraperitoneally 18 hours prior to LPS infusion.

Rats received either 1 mg/kg Salmonella typhosa LPS (Lot 81H4018; Sigma Chemical Co., St Louis, MO, USA) or an...
equivalent volume of normal saline as control via the carotid artery. We have previously found arterial injection of LPS with mechanical ventilation to cause acute lung injury within 4 hours of injection. After 1 hour of spontaneous respiration to allow for development of a septic response, ventilation was begun. We used an established rodent model of mechanical ventilation as previously described [12-14]. Rats were sacrificed with an overdose of pentobarbital after 4 hours of ventilation. The left lung was lavaged with normal saline for measurement of cell counts and cytokines, macrophage inflammatory protein-2 (MIP-2) and TNFα. The right lung was flash frozen for the myeloperoxidase assay, for extraction of RNA for the measurement of HA synthase, and for determining the gene expression of cytokines, MIP-2 and TNFα. Separate groups of animals were used for determination of lung pathology.

**Model of lipopolysaccharide-induced lung injury with mechanical ventilation and therapeutic treatment with hyaluronan**

Rats were ventilated in the same manner as described for the pretreatment with HA model. The 0.35% concentration of 1,600 kDa HA was too viscous for intravenous injection. For the studies post acute lung injury treatment, we performed dose–response studies with 0.025%, 0.05% and 0.1% of 1,600 kDa HA starting at the time of initiation of ventilation. Intravenous infusion of 0.1% sodium carboxymethyl cellulose (CMC) – a positive charged carbohydrate prepared from carboxymethylation of cellulose with a molecular weight of $1 \times 10^5$ to $7.5 \times 10^5$ – was used as a control condition for charge at 500 μl/hour. The infusion was continued throughout the experiment.

**Bronchoalveolar lavage**

The lungs were removed en bloc and tubing was inserted into the trachea and secured. The right lung was clamped at the bronchus to prevent the lavage fluid from entering the right lung. The left lung was lavaged with 2 ml of 0.9% normal saline three times. One millilitre of the pooled effluents was used for cytopsin and subsequent cell differentials, and 100 μl was used for the total cell counts. The remaining effluents were centrifuged at 3,000 rpm for 10 minutes, after which the supernatants were frozen at -80°C for further measurement of cytokines.

**Bronchoalveolar lavage cell counts**

Neutrophil counts in BAL fluid were used to measure migration of neutrophils into alveoli and airways [15]. Total cell counts in BAL were performed using a hemocytometer. To measure cell differentials, the cells in the lavage fluid were fixed on glass slides with cytopsin and were then stained with a hemato logic stain kit (Fisher Diagnostics, Middletown, VA, USA).

**Myeloperoxidase assay**

Myeloperoxidase activity in lung parenchyma was used as a marker of total lung neutrophil sequestration, including neutrophils marginalized in the vasculature, and in the interstitium and alveoli [13,15,16]. Samples of the right lower lobe were obtained within a few minutes of death and were stored at -80°C. The right lower lobe was thawed on ice, weighed, and homogenized in 5 ml phosphate buffer (20 mM, pH 7.4). One milliliter of the homogenate was centrifuged at 10,000 × g for 10 minutes at 4°C. The resulting pellet was resuspended in 1.0 ml phosphate buffer (50 mM, pH 6.0) containing 0.5% hexadecyltrimethylammonium bromide (Sigma Chemical Co.). The suspension was subjected to three cycles of freezing (on dry ice) and thawing (at room temperature), after which it was sonicated for 40 seconds and centrifuged again at 10,000 × g for 5 minutes at 4°C.

The supernatant was assayed for myeloperoxidase activity by measurement of hydrogen peroxide-dependent oxidation of 3,3',5,5'-tetramethylbenzidine (Sigma Chemical Co.). In its oxidized form, 3,3',5,5'-tetramethylbenzidine was measured by spectrophotometer at 650 nm. The reaction mixture for analysis consisted of 25 μl tissue samples, 25 μl 3,3',5,5'-tetramethylbenzidine (final concentration, 0.16 mM) dissolved in dimethylsulfoxide, and 200 μl hydrogen peroxide (final concentration, 0.30 mM) dissolved in phosphate buffer (0.08 M, pH 5.4) prior to adding to the mixture. The reaction mixture was incubated for 3 minutes at 37°C and the reaction stopped by adding 1 ml sodium acetate (0.2 M, pH 3.0), after which absorbance at 650 nm was measured. The absorbance followed a linear relationship with the myeloperoxidase concentration, which in turn is an enzyme marker for leukosequestration. The absorbance ($A_{650}$) was reported as units (optical density) per gram of wet lung weight.

**Measurement of MIP-2 and TNFα in lavage fluid**

Rat MIP-2 and TNFα were measured in BAL fluid using a commercially available ELISA kit containing antibodies that were cross-reactive with rats and mouse MIP-2 (BioSource International, Inc., Camarillo, CA, USA). Each sample was run in duplicate according to the protocol provided by the manufacturer.

**Isolation of RNA and measurement of mRNA expression by RT-PCR**

For isolation of total RNA, the lungs were homogenized in 1.5 ml Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) and were isolated according to the manufacturer’s protocol. Total RNA (1 μg) was reversely transcribed into cDNA using a Gene Amp PCR system 9600 (PerkinElmer Life Sciences, Boston, MA, USA), as previously described [17].

The following primers of MIP-2 were used: PCR forward primer, 5’-TCC TCA ATG CTC TAC TGG TTC-3’ and reverse primer, 5’-ATG TTC TTC TCC AGG TC-3’; TNFα forward primer, 5’-CAT GAT CCG AGA TGT GGA ACT-3’ and
reverse primer, 5'-TCA CAG AGC AAT GAC TCC AAA G-3'; and GAPDH (internal control) forward primer, 5'-AAT GCA TCC TGC ACC ACC AA-3' and reverse primer, 5'-GTA GCC ATA TTC ATT GTC ATA-3' (Sigma Chemical Co.).

The following cycling parameters were used: MIP-2, denaturation at 94°C for 5 minutes followed by 35 cycles of 94°C for 30 seconds, annealing at 50°C for 45 seconds, and extension at 72°C for 30 seconds, with a terminal extension at 72°C for 7 minutes; and for TNFα, denaturation at 94°C for 5 minutes followed by 40 cycles of 94°C for 30 seconds, annealing at 58°C for 45 seconds, and extension at 72°C for 1 minute, with a terminal extension at 72°C for 7 minutes.

Results

Systolic pressure, heart rate and airway pressure in ventilated rats with hyaluronan pretreatment

For animals in the experiments involving HA pretreatment, the systolic pressure was maintained with infusion of saline as needed to maintain systolic blood pressure >70 mmHg to minimize the confounding effects of hypotension. The amount of saline infused did not differ among groups. The peak airway pressures for all animals were between 8 and 12 mmHg. The systolic blood pressure did not differ among groups. The heart rate was increased in animals exposed to LPS but was not significantly different between treatment groups (Table 1).

Pathology

After 4 hours of mechanical ventilation, the rats were sacrificed and the lung and trachea were removed. The left lung was infused at a pressure of 30 cmH2O with 10% buffered formalin, embedded in paraffin, sectioned at 4 μm thickness, and stained with hematoxylin and eosin. Ten randomly chosen fields in the parenchyma (without large airways) from the individual three lungs from each group were examined. Each of the pathological changes was scored on a scale of 0 to 3: 0 = alveolar filling, collapse or atelectasis (10×); 1 = inflammatory cell infiltration in the air space or vessel wall (20×); 2 = perivascular clubbing or swelling (10×); and 3 = alveolar hemorrhage or congestion (10×). The 10 randomly chosen fields at low power (10×) covered over 80% of the left lung. Because the injury was patchy, this technique gave an overview of the whole left lung. A higher power (20×) was needed to accurately identify inflammatory cell infiltration. The overall score was the sum of the average score for each category. Two subspecialists who were blinded to the treatment groups reviewed the degree of injury of each slides.

Table 1

| Hemodynamics in the pretreatment model | Systolic blood pressure | Heart rate |
|----------------------------------------|-------------------------|------------|
|                                        | Baseline | 4 hours | Baseline | 4 hours |
| Group |                     |          |           |          |
| Control | 98 ± 7 | 85 ± 7 | 360 ± 7 | 327 ± 10 |
| Lipopolysaccharide alone | 100 ± 7 | 79 ± 5 | 436 ± 11 | 386 ± 11* |
| Lipopolysaccharide + 1,600 kDa hyaluronan | 112 ± 7 | 96 ± 9 | 405 ± 64 | 412 ± 67* |
| Lipopolysaccharide + 35 kDa hyaluronan | 100 ± 8 | 79 ± 7 | 369 ± 66 | 382 ± 65* |

There were no statistical differences between groups for systolic blood pressure. In the lipopolysaccharide-exposed groups the heart rate was statistically higher, but there were no statistical differences between treatment groups. *P < 0.05 versus control.
Available online http://ccforum.com/content/12/4/R102

on pathology slides (Figure 2). The lung injury score of the rats receiving LPS was significantly greater compared with rats without LPS (Figure 3). We found that rats with LPS receiving 1,600 kDa HA pretreatment, but not 35 kDa HA pretreatment, had less evidence of lung injury on pathology and had significantly decreased lung injury scores (Figures 2 and 3). The inhibition of lung injury by 1,600 kDa HA and not 35 kDa HA correlated with 1,600 kDa HA inhibition of IL-1β.

### Pretreatment with both 1,600 kDa and 35 kDa hyaluronan inhibited lipopolysaccharide-induced MIP-2 and TNFα mRNA and protein production with mechanical ventilation

In a comparison between rats with and without LPS at the same tidal volume, rats with LPS showed increased MIP-2 and TNFα mRNA and protein levels compared with rats without LPS. Rats receiving either 1,600 kDa HA or 35 kDa HA pretreatment showed less MIP-2 and TNFα production at the mRNA and protein level compared with rats with sepsis (Figures 4 and 5).

### Systolic blood pressure and heart rate in rats treated with HMW HA (1,600 kDa) 1 hour post lipopolysaccharide infusion

To further investigate the use of HMW HA infusion as a treatment for sepsis-induced lung injury, HMW HA (0.025%, 0.5% and 0.1%) was infused at 0.5 ml/hour starting at the time of ventilation. For these experiments, the maximum dose of LPS (3 mg/kg) that allowed survival of the animals was used. Saline was infused as needed to maintain a systolic pressure of about 70 mmHg to eliminate the confounding effects of hypotension. The systolic blood pressure was not significantly different between groups.

The heart rate was significantly higher in animals exposed to LPS, there were no significant differences between HMW HA-treated groups, and animals treated with CMC had a higher heart rate than those exposed to 0.1% HMW HA and than control animals (Table 2). All doses of HA and CMC increased the arterial oxygen pressure levels significantly (P < 0.05) above LPS-exposed animals (LPS, 51 ± 10 mmHg; LPS + 0.025% HA, 84 ± 7 mmHg; LPS + 0.05% HA, 67 ± 3 mmHg; LPS + 0.1% HA and LPS + 0.1% CMC, 75 ± 7 mmHg).

### Treatment with HMW HA (1,600 kDa) 1 hour post lipopolysaccharide infusion blocked both lung neutrophil infiltration and acute lung injury in a dose-dependent manner

HMW HA inhibited neutrophil infiltration (Figure 6), MIP-2 mRNA expression (data not shown), and acute lung injury scores (Figure 7) in a dose-dependent manner. To evaluate whether this effect was secondary to the positive charge of HA or to the anti-inflammatory properties of HA, 0.1% CMC was infused at 0.5 ml/hour. CMC at an equal concentration to HMW HA (0.1%) partially blocked lung neutrophil infiltration (Figure 6) and lung injury (Figure 7), but not to the same extent as HMW HA – suggesting that the positive charge of HMW HA was at least partially responsible for the therapeutic effects.
Post-treatment with intraperitoneal HMW HA failed to protect against inhalation acute lung injury, and therefore was not used in the present study (data not shown).

**Discussion**

In the present study we investigated whether administration of exogenous HMW HA could be used as a therapy for sepsis-induced acute lung injury with mechanical ventilation. We demonstrated that pretreatment with HMW HA (1,600 kDa) inhibited inflammatory cell infiltration, cytokine production, and lung injury with mechanical ventilation. LMW HA (35 kDa) inhibited lung neutrophil infiltration and cytokine production, but did not inhibit lung injury or lung monocyte infiltration. HMW HA used in a therapeutic manner 1 hour after LPS infusion inhibited LPS-induced lung inflammation and lung injury in a dose-dependent manner.

HMW HA is an effective treatment in a variety of disease conditions. HMW HA has been shown to be a beneficial treatment for osteoarthritis. HMW HA can downregulate proinflammatory cytokines including IL-8, TNFα, and inducible nitric oxide synthase in fibroblast-like synoviocytes [18]. HMW HA prevented acute liver injury by reducing plasma MIP-2, TNFα, and IFNγ in a T-cell-mediated liver injury mouse model [11]. HMW HA has been shown to be protective in animal models of emphysema, can decrease the number of acute infections in chronic bronchitis in humans, can block group A streptococcus colonization in mice, can block pancreatic elastase-induced bronchoconstriction and neutrophil elastase-induced airway responses in sheep, can decrease peritoneal permeability secondary to infection in rats, and can reduce exercise-induced airway hyperreactivity in humans [19-23]. Beneficial effects in sepsis, however, have not been previously demonstrated.

Our findings are consistent with previous observations that mice overexpressing HMW HA are protected from bleomycin-induced lung injury [9]. Both HAS 1 and HAS 2 produced HMW HA. HASs are located on the cell surface and secrete the chains of HA into the extracellular matrix [1]. We have found in the normal lung that HA is of the HMW HA form; however, in high-tidal-volume-induced lung injury in rats we found both HMW HA and LMW HA.

To establish whether HMW HA could potentially have beneficial effects in the treatment of sepsis we initially used pretreatment with an intraperitoneal injection of 35% HMW HA prior to LPS injection. This concentration, given intraperitoneally 18 hours before liver injury, has been shown to be absorbed into the systemic circulation and to prevent concavalin-induced liver injury [11]. We then explored the use of HMW HA as a treatment for sepsis-induced lung injury. We had in previous studies found that HMW HA given intraperitoneally after smoke inhalation failed to protect lung injury (data not shown), probably related to delayed absorption, and 35% HMW HA...
was too viscous for intravenous injection. We therefore used continuous infusion of 0.025%, 0.05% and 0.1% HMW HA, concentrations that allowed intravenous infusion, starting 1 hour after injection of LPS.

We used intra-arterial LPS rather than the more conventional intravenous route of injection. We designed our model to produce lung injury over a 4-hour period that did not result in death but in a lung injury that was increased by high-tidal-volume ventilation over this period. We studied both venous and arterial injection. With arterial injection we found that there was increased neutrophil infiltration with arterial injection (61 × 10^3 ± 10 cells/ml BAL fluid) than with venous injection (23 × 10^3 ± 1 cells/ml BAL fluid, \( P < 0.05 \)). Based on this response we chose the intra-arterial route. Intra-arterial injection has been used in other models of sepsis [24,25].

The difference in effects on acute lung injury scores between HMW HA and LMW HA may have been related to the different effects of the two molecular weights. HMW HA may block the effects of LMW HA produced in lung injury. The breakdown of HMW HA causes HA fragments to increase quickly and markedly in response to endotoxin [26], and elevated levels of plasma HA fragments have been detected in patients with

Figure 4

Hyaluronan (1,600 kDa and 35 kDa) inhibited cytokine mRNA expression. Animals were pretreated with either 1,600 kDa or 35 kDa hyaluronan 18 hours prior to ventilation. Lipopolysaccharide (LPS) (1 mg/kg) was given by arterial injection 1 hour prior to the start of ventilation. After 4 hours of ventilation, animals were sacrificed and the right upper lobe was flash frozen for extraction of RNA. Macrophage inflammatory protein-2 (MIP-2) and TNFα mRNA expression was decreased with high-molecular-weight hyaluronan or low-molecular-weight hyaluronan. (a) RT-PCR. (b) Quantitation of mRNA expression for MIP-2. (c) Quantitation of mRNA expression for TNFα. C, Control; L, LPS. * \( P < 0.05 \) versus control, \# \( P < 0.05 \) versus LPS.

Figure 5

Pretreatment with hyaluronan (1,600 kDa and 35 kDa) inhibited cytokine protein expression. Animals were pretreated with either 1,600 kDa or 35 kDa hyaluronan 18 hours prior to ventilation. Lipopolysaccharide (LPS) (1 mg/kg) was given by arterial injection 1 hour prior to the start of ventilation. After 4 hours of ventilation, animals were sacrificed and the left lung was lavaged. Cytokine protein expression in bronchoalveolar lavage fluid (BAL) when measured by ELISA. Macrophage inflammatory protein-2 (MIP-2) and TNFα protein expression was decreased with high-molecular-weight hyaluronan or low-molecular-weight hyaluronan. (a) MIP-2. (b) TNFα. * \( P < 0.05 \) versus control, \# \( P < 0.05 \) versus LPS. Non-vent, nonventilated.
septicemia [27]. LMW HA (200 kDa) isolated from the serum of patients with acute lung injury stimulated cytokine production in macrophages [9]. LMW HA mediates bleomycin-induced lung injury [9,28-31].

In previous studies, we demonstrated that de novo synthesis of LMW HA by HAS 3 was induced in lung fibroblasts exposed to cyclic stretch via tyrosine kinase signaling pathways [7]. In vivo, very-high-tidal-volume ventilation (30 ml/kg) induced LMW HA production, was dependent on HAS 3, and resulted in increased neutrophil infiltration in the lungs of mice [8]. Alternatively, the beneficial effects of HMW HA inhibition on inflammation may have been secondary to an increase in the ratio of HMW HA to LMW HA, thereby maintaining the level of HMW HA in the extracellular matrix and maintaining the integrity of the extracellular matrix [4,29].

HA receptors include CD44, RHAMM, Toll-like receptor 2 and Toll-like receptor 4 [9,32-34]. LMW HA induces cytokine production by binding to HA cell surface receptors. LMW HA (200 kDa) isolated from the serum of patients with acute lung injury stimulated cytokine production by binding to Toll-like receptor 2 and Toll-like receptor 4. LMW HA binding to Toll-

**Table 2**

**Hemodynamics in the treatment model**

| Group                                      | Systolic blood pressure | Heart rate |
|--------------------------------------------|-------------------------|------------|
|                                            | Baseline | 4 hours | Baseline | 4 hours |
| Control                                   | 125 ± 6  | 88 ± 6  | 425 ± 25 | 327 ± 9  |
| LPS alone                                 | 98 ± 8   | 70 ± 5  | 465 ± 11 | 438 ± 28* |
| LPS + 0.025% of 1,600 kDa HMW HA          | 125 ± 5  | 72 ± 8  | 442 ± 21 | 448 ± 9*  |
| LPS + 0.5% of 1,600 kDa HMW HA            | 112 ± 9  | 86 ± 6  | 475 ± 17 | 445 ± 10* |
| LPS + 0.1% of 1,600 kDa HMW HA            | 97 ± 16  | 87 ± 6  | 495 ± 18 | 401 ± 23* |
| LPS + 0.1% sodium carboxymethyl cellulose | 97 ± 8   | 85 ± 7  | 464 ± 18 | 474 ± 30* † |

There were no statistical differences between groups for systolic blood pressure. In the lipopolysaccharide (LPS)-exposed groups the heart rate was statistically higher, but there were no statistical differences between the high-molecular-weight hyaluronan (HMW HA) treatment groups. LPS + 0.1% sodium carboxymethyl cellulose was statistically higher than LPS + 0.1% HMW HA. *P < 0.01 versus control. †P < 0.01 versus LPS + 0.1% HMW HA.

High-molecular-weight hyaluronan (1,600 kDa) given after lipopolysaccharide infusion blocked neutrophil infiltration in a dose-dependent manner. Animals were infused with 0.025%, 0.05%, or 0.1% high-molecular-weight hyaluronan (HMW HA) or 0.1% sodium carboxymethyl cellulose (CMC) at 500 μl/hour starting 1 hour after lipopolysaccharide (LPS) (3 mg/kg) infusion. Intravenous HMW HA given post LPS infusion showed a dose-dependent decrease in neutrophil infiltration, which was only partially explained by charge – as evidenced by significantly less inhibition with 0.1% CMC, a positively charged carbohydrate of similar molecular weight, as compared with 0.1% HMW HA. *P < 0.05 versus LPS, #P < 0.05 versus LPS + 0.1% HMW HA. BAL, bronchoalveolar lavage.

High-molecular-weight hyaluronan (1,600 kDa) given after lipopolysaccharide infusion blocked lung injury in a dose-dependent manner. Animals were infused with 0.025%, 0.05%, or 0.1% high-molecular-weight hyaluronan (HMW HA) or 0.1% sodium carboxymethyl cellulose (CMC) at 500 ml/hour starting 1 hour after lipopolysaccharide (LPS) infusion. *P < 0.05 versus LPS, #P < 0.05 versus LPS + 0.1% HMW HA.
like receptor 2 and Toll-like receptor 4 initiates mRNA expression by activation of the JNK pathways and through MyD88 activation [9,33,34]. HMW HA has been shown to block the action of LMW HA by competing LMW HA binding to its receptors [35]. The beneficial effects of HMW HA in this model of sepsis may have been secondary to HMW HA blocking the binding of LPS or LMW HA to Toll-like receptors, which mediate inflammation.

Surprisingly, infusion of LMW HA – at the size (35 kDa) and concentration (up to 1%) used in the present study – did not cause increased inflammation, and actually inhibited lung inflammation. LMW HA has been found to be proinflammatory by many authors, but not in all studies. Other authors have found that it is the protein and DNA contamination found in the LMW HA that is proinflammatory, and not the LMW HA itself [10,36]. One explanation of the lack of proinflammatory effects of the HA used in this study is the purity of the compound. The HA used in the present study has <0.1% protein and <0.1 absorbance units of nucleotides. We cannot rule out longer exposures or higher concentrations of LMW HA or other sizes of LMW HA causing inflammation. Since the 35 kDa LMW HA failed to prevent acute lung injury on pathology in our pretreatment studies, we did not use LMW HA in the postinjury studies.

Both HMW HA and LMW HA inhibited MIP-2 production in the BAL and inhibited infiltration of neutrophils and monocytes into the lung. The inhibition of MIP-2 most probably accounts for this effect. It has been previously shown that a gradient of chemokines between the alveoli and the circulation is needed to induce migration into the alveolar space [15]. We have previously shown that neutralization of MIP-2 in the airways prevents lung inflammatory cell infiltration in ventilator-induced lung inflammation [13].

Alternatively the beneficial effects were not secondary HMW HA inhibition of LMW HA, but secondary to an increase in the ratio of HMW HA to LMW HA – thereby maintaining the level of HMW HA in the extracellular matrix and maintaining the integrity of the extracellular matrix [4], and preventing the influx of inflammatory cytokines into the alveoli. This maintenance of the extracellular matrix may be an important mechanism in the prevention of acute lung injury by HMW HA.

Infusion of CMC, a carbohydrate with a positive charge similar size to the HMW HA, was used to control for the effects of charge. CMC blocked inflammation and lung injury – but not to the same extent as HMW HA. Since LMW HA and CMC partially blocked lung inflammation, the positive charge of HA may play a role in preventing lung injury by binding negatively charged inflammatory proteins.

One limitation of our study comparing LMW HA and HMW HA is the difference in molarity between the two infusions. We were unable to match molarity with the two infusions, since the high concentration of LMW HA that would be necessary to match the molarity between the solutions was not soluble. We cannot rule out that the beneficial effects of HMW HA may be due to the higher molarity of the solution being a better method of fluid resuscitation. We used additional saline infusions, however, to maintain the systolic blood pressure above 70 mmHg to eliminate hypotension as a confounding factor. The systolic blood pressure did not differ between groups.

An important part of our model is the use of mechanical ventilation with LPS infusion. The management of acute respiratory failure requires the use of positive-pressure mechanical ventilation to provide adequate ventilation and oxygenation. But mechanical ventilation with a high tidal volume leads to ventilator-induced lung injury by alveolar overdistention coupled with repeated collapse and reopening during mechanical ventilation, which initiates a cascade of proinflammatory cytokines. Even mechanical ventilation with moderate tidal volumes can augment the sepsis-induced lung injury by synergistically increasing lung cytokines, and may play a pivotal role in the development of acute lung injury in patients with sepsis [37-40]. The augmentation of acute lung injury by high tidal volumes has been termed ventilator-associated lung injury.

Conclusion
HMW HA attenuated both lung inflammation and the extent of lung injury in a rat model of sepsis with mechanical ventilation, whereas LMW HA only inhibited lung inflammation and not the acute lung injury scores. These findings of the beneficial effects of HA in sepsis-induced lung injury are intriguing and warrant further investigation. Since LMW HA and CMC, a carbohydrate with a positive charge, also partially blocked lung inflammation, the size of HA may not be the only factor involved in the prevention of lung inflammation.

Key messages

- HMW HA can inhibit acute lung injury secondary to sepsis.
- LMW HA was not as effective in inhibiting acute lung injury, but did inhibit inflammation.
- The mechanism of HMW HA inhibition of acute lung injury may be secondary to the positive charge of the molecule as well as to the size of the molecule.

Competing interests
HGG, CAH, and DAQ initiated a patent application for the use of HMW HA in the treatment of sepsis. DAQ received an unrestricted grant for the support of this work. DAQ now works for Novartis Pharmaceuticals, who did not support this work and are not involved in this work in any way. AS is employed by the Genzyme Corporation, who supported the patent application.
All other authors declare that they have no competing interests.

Authors’ contributions
Y-YH and C-HL should be considered co-first authors: Y-YH is responsible for the work with pretreatment with hyaluronan, and C-HL is responsible for the work on hyaluronan as a therapeutic agent. Y-YH was responsible for carrying out the experiments and for data analysis in the pretreatment experiments. C-HL was responsible for carrying out the experiments and for data analysis in the therapeutic treatment experiments. HZ was responsible for the analysis for the PCR measurements. RD carried out the PCR measurements and performed the analysis under the guidance of HZ. AS provided all of the HA used in the experiments. OS oversaw the animal experiments, instructed Y-YH and C-HL in their implementation, and supervised the procurement and processing of the histology and myeloperoxidase assays. HGG is an expert in hyaluronan experiments and assisted in the experimental design. CAH is an expert in pulmonary physiology, assisted in the experimental design, and assisted in the data analysis and interpretation. DAQ is the principal investigator who initiated the project, designed the experiments, and oversaw the interpretation of the data. HM was responsible for performing and analyzing the control experiments. P-HM assisted in the assessment of the pathology.

Acknowledgements
The authors thank Susannah Wood for her generous support and encouragement, and thank John Beagle and Lunyin Yu for their expert assistance. JA is an expert in pulmonary physiology, assisted in the experimental design, and assisted in the data analysis and interpretation. HZ oversaw the animal experiments. OS oversaw the animal experiments, instructed Y-YH and C-HL in their implementation, and supervised the procurement and processing of the histology and myeloperoxidase assays. HGG is an expert in hyaluronan experiments and assisted in the experimental design. CAH is an expert in pulmonary physiology, assisted in the experimental design, and assisted in the data analysis and interpretation. DAQ is the principal investigator who initiated the project, designed the experiments, and oversaw the interpretation of the data. HM was responsible for performing and analyzing the control experiments. P-HM assisted in the assessment of the pathology.

References
1. Philipson LH, Schwartz NB: Subcellular localization of hyaluronate synthetase in oligodendroglia cells. J Biol Chem 1984, 259:5017-5023.
2. Spicer AP, McDonald JA: Characterization and molecular evolution of a vertebrate hyaluronan synthase gene family. J Biol Chem 1998, 273:1923-1932.
3. Itano N, Sawani T, Lenas P, Yamada Y, Imagawa M, Shinomura T, Hamaguchi M, Yoshida Y, Ohnuki Y, Miyaiuchi S, Spicer AP, McDonald JA, Kimata K: Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem 1999, 274:25085-25092.
4. Noble PW: HA in lung function. Overview. In Proteoglycans in Lung Disease Edited by: Garg HG, Roughley PJ, Hales CA. New York: Marcel Dekker; 2002:23-36.
5. Horton MR, McKeen CM, Bao C, Liao F, Farber JM. Hodge-Dufour J, Pure E, Oliver BL, Wright TM, Noble P: Hyaluronan fragments synergize with interferon-gamma to induce the C-X-C chemokines mig and interferon-inducible protein-10 in mouse macrophages. J Biol Chem 1998, 273:35098-35094.
6. Boodoo S, Spannhake EW, Powell JD, Horton MR: Differential regulation of hyaluronan-induced IL-8 and IP-10 in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006, 291:479-486.
7. Maccarenhas MM, Day RM, Ochoa CD, Choi W, Yu L, Ouyang B, Garg HG, Hales CA, Quinn DA: Low molecular weight hyaluronan from stretched lung enhances IL-8 expression. Am J Respir Cell Mol Biol 2004, 30:51-60.
8. Bai KJ, Spicer AP, Mascarenhas MM, Yu L, Ochoa CD, Garg HG, Quinn DA: The role of hyaluronan synthase 3 in ventilator-induced lung injury. Am J Respir Crit Care Med 2005, 172:92-98.
9. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestuiuch GD, Mascarenhas M, Garg HG, Quinn DA, Homer RJ, Goldstein DR, Bucala , Lee PJ, Medshtov R, Nobel FW: Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005, 11:1173-1179.
10. Shiedlin A, Bigelow R, Christopher W, Arbabi S, Yang L, Maier RV, Wainwright N, Childs A, Miller RJ: Evaluation of hyaluronan from different sources: Streptococcus zooepidemicus, rooster comb, bovine vitreous, and human umbilical cord. Bioorganic-molecules 2004, 5:2122-2127.
11. Nakamura K, Yokohama S, Yoneda M, Okamoto S, Tamaki Y, Ito T, Okada M, Aso K, Maxino I: High, but not low, molecular weight hyaluronan prevents T-cell-mediated liver injury by reducing proinflammatory cytokines in mice. J Gastroenterol 2004, 39:346-354.
12. Hales CA, Du HK, Volokhov A, Moufarrej RK, Quinn DA: Aquaporin channels may modulate ventilator-induced lung injury. Respir Physiol Neurobiol 2003, 137:15-22.
13. Quinn DA, Moufarrej RK, Volokhov A, Hales CA: Interactions of lung stretch, hyperoxia, and MIP-2 production in ventilator-induced lung injury. J Appl Physiol 2002, 93:517-525.
14. Choi W, Quinn DA, Park KM, Moufarrej RK, Jafari B, Syrjana O, Bocciorente JV, Hales CA: Systemic microvascular leak in an in vivo rat model of ventilator-induced lung injury. Am J Respir Crit Care Med 2003, 167:1627-1632.
15. Blackwell TS, Lancaster LH, Blackwell TR, Venkatakakrishnan A, Christman JW: Chemotactic gradients predict neutrophilic alveolitis in endotoxin-treated rats. Am J Respir Crit Care Med 1999, 159:1644-1652.
16. Goldblum SE, Wu KM, Jay M: Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J Appl Physiol 1985, 58:1979-1985.
17. Yu L, Quinn DA, Garg HG, Hales C: Gene expression of cyclin-dependent kinase inhibitors and effect of heparin on their expression in mice with hypoxia-induced pulmonary hypertension. Biochem Biophys Res Commun 2006, 345:1565-1572.
18. Wang CT, Lin YT, Chiang BL, Lin YH, Hou SM: High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage 2006, 14:1237-1247.
19. Turino GM, Cantor JO: Hyaluronan in respiratory injury and repair. Am J Respir Crit Care Med 2003, 167:1169-1175.
20. Scuci M, Abraham WM: Hyaluronan blocks human neutrophil elastase (HNE)-induced airway responses in sheep. Pulm Pharmacol Ther 2003, 16:335-340.
21. Scuci M, Abraham WM, Bobitnikova Y, Forteza R: Hyaluronic acid blocks porcine pancreatic elastase (PPE)-induced bronchoconstriction in sheep. Am J Respir Crit Care Med 2001, 164:1855-1859.
22. Polubinska A, Pawlaczyk K, Kuzlan-Pawlaczyk M, Wieczorowska-Tobis K, Chen C, Moberly JB, Martis L, Breborowicz A, Oreopoulos DG: Dialysis solution containing hyaluronan: effect on peritoneal permeability and inflammation in rats. Kidney Int 2000, 57:1182-1189.
23. Breborowicz A, Polubinska A, Moberly J, Ogle K, Martis L, Oreopoulos D: Hyaluronan inhibits inflammatory response and peritoneal permeability during peritonitis in rats. Am J Kidney Dis 2001, 37:594-600.
24. Han JY, Horie Y, Miura S, Akiba Y, Guo J, Li D, Fan JY, Hu BH, Chang X, Xu M, Guo DA, Sun K, Yang JY, Fang SP, Xian MJ, Kikuchi M, Nagata H, Hibi T: Mucosal dexamethasone injection improves endotoxin-induced microcirculatory disturbance in rat mesentery. World J Gastroenterol 2007, 13:3581-3591.
25. Rummel C, Hubschle T, Gerstberger R, Roth J: Nuclear translocation of the transcription factor STAT3 in the guinea pig brain during systemic or localised inflammation. J Physiol 2004, 557:671-687.
26. Blackwood RA, Cantor JO, Moret J, Mandl I, Turino GM: Glycosaminoglycan synthesis in endotoxin-induced lung injury. Proc Soc Exp Biol Med 1983, 174:343-349.
27. Berg S, Jansson I, Hesselvik FJ, Laurent TC, Lennquist S, Walther S: Hyaluronan: relationship to hemodynamics and survival in porcine injury and sepsis. Crit Care Med 1992, 20:1315-1321.

28. Savani RC, Hou G, Liu P, Wang C, Simons E, Grimm PC, Stern R, Greenberg AH, DeLisser HM, Khalil N: A role for hyaluronan in macrophage accumulation and collagen deposition after bleomycin-induced lung injury. Am J Respir Cell Mol Biol 2000, 23:475-484.

29. Teder P, Vandivier RW, Jiang D, Liang J, Cohn L, Pure E, Henson PM, Noble PW: Resolution of lung inflammation by CD44. Science 2000, 296:155-158.

30. McKee CM, Penno MB, Cowman M, Burdick MD, Strieter RM, Bao C, Noble PW: Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 1996, 98:2403-2413.

31. O'Neill LAJ: TLRs play good cop, bad cop in the lung. Nat Med 2005, 11:1161-1162.

32. Turley EA, Noble PW, Bourguignon L: Signaling properties of hyaluronan receptors. J Biol Chem 2002, 277:4589-4592.

33. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR: Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 2006, 177:1272-1281.

34. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL: Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004, 279:17079-17084.

35. Day AJ, de la Motte CA: Hyaluronan cross-linking: a protective mechanism in inflammation? Trends Immunol 2005, 26:637-643.

36. Filion MD, Phillips NC: Pro-inflammatory activity of contaminating DNA in hyaluronic acid preparations. J Pharm Pharmacol 2001, 53:551-561.

37. Altemeier WA, Matute-Bello G, Frevert CW, Kawata Y, Kajikawa O, Martin TR, Glenny RW: Mechanical ventilation with moderate tidal volumes synergistically increases lung cytokine response to systemic endotoxin. Am J Physiol Lung Cell Mol Physiol 2004, 287:L533-L542.

38. Altemeier WA, Matute-Bello G, Gharib SA, Glenny RW, Martin TR, Liles WC: Modulation of lipopolysaccharide-induced gene transcription and promotion of lung injury by mechanical ventilation. J Immunol 2005, 175:3369-3376.

39. Bregenon F, Delpierre S, Chetaille B, Kajikawa O, Martin TR, Autillo-Touati A, Jammes Y, Pugin J: Mechanical ventilation affects lung function and cytokine production in an experimental model of endotoxemia. Anesthesiology 2005, 102:331-339.

40. Gajic O, Frutos-Vivar F, Esteban A, Hubmayr RD, Anzueto A: Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients. Intensive Care Med 2005, 31:922-926.